Market closed
GH Research/$GHRS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Ticker
$GHRS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
49
Website
GH Research Metrics
BasicAdvanced
$491M
-
-$0.80
0.74
-
Price and volume
Market cap
$491M
Beta
0.74
52-week high
$14.99
52-week low
$6.00
Average daily volume
91K
Financial strength
Current ratio
15.832
Quick ratio
15.33
Long term debt to equity
0.242
Total debt to equity
0.387
Interest coverage (TTM)
-66.69%
Management effectiveness
Return on assets (TTM)
-14.02%
Return on equity (TTM)
-19.96%
Valuation
Price to book
2.59
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
-12.274
Growth
Earnings per share change (TTM)
1.28%
3-year earnings per share growth (CAGR)
77.29%
What the Analysts think about GH Research
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for GH Research stock.
GH Research Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GH Research Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
GH Research News
AllArticlesVideos
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
GlobeNewsWire·3 weeks ago
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewsWire·3 months ago
3 Fast-Growing Stocks Analysts See Doubling in Price
MarketBeat·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for GH Research stock?
GH Research (GHRS) has a market cap of $491M as of January 31, 2025.
What is the P/E ratio for GH Research stock?
The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of January 31, 2025.
Does GH Research stock pay dividends?
No, GH Research (GHRS) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next GH Research dividend payment date?
GH Research (GHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for GH Research?
GH Research (GHRS) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.